{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:48:58Z","timestamp":1791294538215,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.4065\/mcp.2011.0287","type":"journal-article","created":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T18:01:02Z","timestamp":1317405662000},"page":"981-990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Circulating Serologic and Molecular Biomarkers in Malignant Melanoma"],"prefix":"10.4065","volume":"86","author":[{"given":"Shanique R.","family":"Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilia","family":"Ichetovkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Knauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.4065\/mcp.2011.0287_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.4065\/mcp.2011.0287_bib2","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.4065\/mcp.2011.0287_bib3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4065\/82.4.490","article-title":"Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment","volume":"82","author":"Markovic","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/mcp.2011.0287_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2217\/fon.09.15","article-title":"Novel therapeutics for the treatment of metastatic melanoma","volume":"5","author":"Mansfield","year":"2009","journal-title":"Future Oncol"},{"key":"10.4065\/mcp.2011.0287_bib5","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.2741\/3065","article-title":"The genetics of malignant melanoma","volume":"13","author":"Lomas","year":"2008","journal-title":"Front Biosci"},{"key":"10.4065\/mcp.2011.0287_bib6","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":"Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.4065\/mcp.2011.0287_bib7","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1002\/1097-0142(19931115)72:10<3091::AID-CNCR2820721034>3.0.CO;2-V","article-title":"Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis","volume":"72","author":"Sirott","year":"1993","journal-title":"Cancer"},{"key":"10.4065\/mcp.2011.0287_bib8","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.1998.16.3.1103","article-title":"Prognostic factors for survival of patients treated systemically for disseminated melanoma","volume":"16","author":"Eton","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.4065\/mcp.2011.0287_bib9","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ejca.2009.04.016","article-title":"LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)","volume":"45","author":"Agarwala","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.4065\/mcp.2011.0287_bib10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejso.2007.04.009","article-title":"A review of the S100 proteins in cancer","volume":"34","author":"Salama","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"10.4065\/mcp.2011.0287_bib11","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.4049\/jimmunol.152.4.1888","article-title":"Acute inflammatory activity of the S100 protein CP-10. Activation of neutrophils in vivo and in vitro","volume":"152","author":"Devery","year":"1994","journal-title":"J Immunol"},{"key":"10.4065\/mcp.2011.0287_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0361-9230(95)00040-2","article-title":"The S100 protein family: history, function, and expression","volume":"37","author":"Zimmer","year":"1995","journal-title":"Brain Res Bull"},{"key":"10.4065\/mcp.2011.0287_bib13","first-page":"69","article-title":"The multifunctional S100 protein family","volume":"172","author":"Heizmann","year":"2002","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.4065\/mcp.2011.0287_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2133.1997.17651853.x","article-title":"Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions","volume":"137","author":"B\u00f6ni","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.4065\/mcp.2011.0287_bib15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/(SICI)1097-0215(19970822)74:4<464::AID-IJC19>3.0.CO;2-9","article-title":"Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma","volume":"74","author":"Maelandsmo","year":"1997","journal-title":"Int J Cancer"},{"issue":"35","key":"10.4065\/mcp.2011.0287_bib16","doi-asserted-by":"crossref","first-page":"27487","DOI":"10.1074\/jbc.M110.155382","article-title":"The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma","volume":"285","author":"Lin","year":"2010","journal-title":"J Biol Chem"},{"key":"10.4065\/mcp.2011.0287_bib17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/286400a0","article-title":"S100 protein is present in cultured human malignant melanomas","volume":"286","author":"Gaynor","year":"1980","journal-title":"Nature"},{"key":"10.4065\/mcp.2011.0287_bib18","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(81)92142-5","article-title":"S100 protein: a marker for human malignant melanomas?","volume":"1","author":"Gaynor","year":"1981","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0287_bib19","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1097-0142(19820901)50:5<912::AID-CNCR2820500519>3.0.CO;2-U","article-title":"Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application","volume":"50","author":"Nakajima","year":"1982","journal-title":"Cancer"},{"key":"10.4065\/mcp.2011.0287_bib20","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/clinchem\/34.7.1387","article-title":"Particle counting immunoassay of S100 protein in serum: possible relevance in tumors and ischemic disorders of the central nervous system","volume":"34","author":"Fagnart","year":"1988","journal-title":"Clin Chem"},{"key":"10.4065\/mcp.2011.0287_bib21","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/0959-8049(95)00087-Y","article-title":"Clinical significance of serum S100 in metastatic malignant melanoma","volume":"31A","author":"Guo","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.4065\/mcp.2011.0287_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00008390-199604000-00008","article-title":"Prognostic value of serum analyses of S-100 beta protein in malignant melanoma","volume":"6","author":"von Schoultz","year":"1996","journal-title":"Melanoma Res"},{"key":"10.4065\/mcp.2011.0287_bib23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000246103","article-title":"Serum S100: a marker for disease monitoring in metastatic melanoma","volume":"194","author":"Henze","year":"1997","journal-title":"Dermatology"},{"key":"10.4065\/mcp.2011.0287_bib24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1365-2133.1997.18531946.x","article-title":"Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma","volume":"137","author":"Abraha","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.4065\/mcp.2011.0287_bib25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000011989","article-title":"S100B protein detection in serum is a significant prognostic factor in metastatic melanoma","volume":"56","author":"Hauschild","year":"1999","journal-title":"Oncology"},{"key":"10.4065\/mcp.2011.0287_bib26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00008390-199710000-00005","article-title":"S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma","volume":"7","author":"K\u00e4rnell","year":"1997","journal-title":"Melanoma Res"},{"key":"10.4065\/mcp.2011.0287_bib27","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/bjc.1998.368","article-title":"The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma","volume":"77","author":"Bonfrer","year":"1998","journal-title":"Br J Cancer"},{"key":"10.4065\/mcp.2011.0287_bib28","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/ijc.23794","article-title":"The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis","volume":"123","author":"Mocellin","year":"2008","journal-title":"Int J Cancer"},{"key":"10.4065\/mcp.2011.0287_bib29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00008390-200510000-00009","article-title":"Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy","volume":"15","author":"Schmidt","year":"2005","journal-title":"Melanoma Res"},{"key":"10.4065\/mcp.2011.0287_bib30","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/bjc.1997.232","article-title":"Elevated serum levels of S100 and survival in metastatic malignant melanoma","volume":"75","author":"Buer","year":"1997","journal-title":"Br J Cancer"},{"key":"10.4065\/mcp.2011.0287_bib31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00008390-200308000-00014","article-title":"S100 serum level: a tumour marker for metastatic melanoma","volume":"13","author":"Bottoni","year":"2003","journal-title":"Melanoma Res"},{"key":"10.4065\/mcp.2011.0287_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00008390-200302000-00008","article-title":"Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma","volume":"13","author":"Hamberg","year":"2003","journal-title":"Melanoma Res"},{"key":"10.4065\/mcp.2011.0287_bib33","first-page":"1311","article-title":"S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase","volume":"21","author":"Kr\u00e4hn","year":"2001","journal-title":"Anticancer Res"},{"key":"10.4065\/mcp.2011.0287_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000048687","article-title":"S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function","volume":"23","author":"Molina","year":"2002","journal-title":"Tumour Biol"},{"key":"10.4065\/mcp.2011.0287_bib35","first-page":"5695","article-title":"Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA","volume":"54","author":"Blesch","year":"1994","journal-title":"Cancer Res"},{"key":"10.4065\/mcp.2011.0287_bib36","first-page":"5358","article-title":"Autocrine tumor cell growth-inhibiting activities from human malignant melanoma","volume":"49","author":"Bogdahn","year":"1989","journal-title":"Cancer Res"},{"key":"10.4065\/mcp.2011.0287_bib37","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1054\/bjoc.2000.1424","article-title":"Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo","volume":"83","author":"Guba","year":"2000","journal-title":"Br J Cancer"},{"key":"10.4065\/mcp.2011.0287_bib38","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00008390-200112000-00009","article-title":"Prognostic significance of melanoma inhibiting activity levels in malignant melanoma","volume":"11","author":"Meral","year":"2001","journal-title":"Melanoma Res"},{"key":"10.4065\/mcp.2011.0287_bib39","first-page":"289","article-title":"Expression, function and clinical relevance of MIA (melanoma inhibitory activity)","volume":"17","author":"Bosserhoff","year":"2002","journal-title":"Histol Histopathol"},{"key":"10.4065\/mcp.2011.0287_bib40","first-page":"3149","article-title":"Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma","volume":"57","author":"Bosserhoff","year":"1997","journal-title":"Cancer Res"},{"key":"10.4065\/mcp.2011.0287_bib41","first-page":"5041","article-title":"MIA as a reliable tumor marker in the serum of patients with malignant melanoma","volume":"20","author":"Stahlecker","year":"2000","journal-title":"Anticancer Res"},{"key":"10.4065\/mcp.2011.0287_bib42","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1078-0432.CCR-08-1980","article-title":"Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma","volume":"15","author":"Nevala","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.4065\/mcp.2011.0287_bib43","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/modpathol.2010.227","article-title":"Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis","volume":"24","author":"Mansfield","year":"2011","journal-title":"Mod Pathol"},{"key":"10.4065\/mcp.2011.0287_bib44","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat Med"},{"key":"10.4065\/mcp.2011.0287_bib45","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood.V92.11.4150","article-title":"Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo","volume":"92","author":"Gabrilovich","year":"1998","journal-title":"Blood"},{"key":"10.4065\/mcp.2011.0287_bib46","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/sj.bjc.6604965","article-title":"Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes","volume":"100","author":"Alfaro","year":"2009","journal-title":"Br J Cancer"},{"key":"10.4065\/mcp.2011.0287_bib47","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","article-title":"VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression","volume":"101","author":"Ohm","year":"2003","journal-title":"Blood"},{"key":"10.4065\/mcp.2011.0287_bib48","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/JCO.2001.19.2.577","article-title":"Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival","volume":"19","author":"Ugurel","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.4065\/mcp.2011.0287_bib49","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00008390-200208000-00004","article-title":"VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course","volume":"12","author":"Osella-Abate","year":"2002","journal-title":"Melanoma Res"},{"key":"10.4065\/mcp.2011.0287_bib50","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2133.2005.06507.x","article-title":"Circulating vascular endothelial growth factor in cutaneous malignant melanoma","volume":"152","author":"Pelletier","year":"2005","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.4065\/mcp.2011.0287_bib51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/107327480901600303","article-title":"Tumor biomarkers in melanoma","volume":"16","author":"Ugurel","year":"2009","journal-title":"Cancer Control"},{"key":"10.4065\/mcp.2011.0287_bib52","first-page":"120","article-title":"Tyrosinase activity in serum from patients with malignant melanoma","volume":"69","author":"Agrup","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"10.4065\/mcp.2011.0287_bib53","first-page":"5073","article-title":"Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy","volume":"57","author":"Wimmer","year":"1997","journal-title":"Cancer Res"},{"key":"10.4065\/mcp.2011.0287_bib54","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00008390-199702000-00009","article-title":"Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression","volume":"7","author":"Hirai","year":"1997","journal-title":"Melanoma Res"},{"key":"10.4065\/mcp.2011.0287_bib55","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00008390-200312000-00008","article-title":"Evaluation of the serum L-dopa\/L-tyrosine ratio as a melanoma marker","volume":"13","author":"Stoitchkov","year":"2003","journal-title":"Melanoma Res"},{"key":"10.4065\/mcp.2011.0287_bib56","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0959-8049(01)00192-7","article-title":"Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma","volume":"37","author":"Vuoristo","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.4065\/mcp.2011.0287_bib57","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1158\/1078-0432.CCR-04-2478","article-title":"High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma","volume":"11","author":"Nikkola","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.4065\/mcp.2011.0287_bib58","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1346-8138.2008.00446.x","article-title":"Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma","volume":"35","author":"Yoshino","year":"2008","journal-title":"J Dermatol"},{"key":"10.4065\/mcp.2011.0287_bib59","first-page":"1405","article-title":"Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden","volume":"2","author":"Mouawad","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.4065\/mcp.2011.0287_bib60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00008390-199502000-00008","article-title":"Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma","volume":"5","author":"Dummer","year":"1995","journal-title":"Melanoma Res"},{"key":"10.4065\/mcp.2011.0287_bib61","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1081\/CNV-100102550","article-title":"Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma","volume":"19","author":"Nemunaitis","year":"2001","journal-title":"Cancer Invest"},{"key":"10.4065\/mcp.2011.0287_bib62","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ijc.10524","article-title":"Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients","volume":"100","author":"Rebmann","year":"2002","journal-title":"Int J Cancer"},{"key":"10.4065\/mcp.2011.0287_bib63","first-page":"3789","article-title":"Soluble HLA class I antigens in plasma of patients with malignant melanoma","volume":"18","author":"Westhoff","year":"1998","journal-title":"Anticancer Res"},{"key":"10.4065\/mcp.2011.0287_bib64","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ijc.21073","article-title":"Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma","volume":"117","author":"Ugurel","year":"2005","journal-title":"Int J Cancer"},{"key":"10.4065\/mcp.2011.0287_bib65","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.0022-202X.2005.23798.x","article-title":"Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma","volume":"125","author":"Vergilis","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.4065\/mcp.2011.0287_bib66","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1089\/aid.2007.0286","article-title":"Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability","volume":"24","author":"Hahn","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.4065\/mcp.2011.0287_bib67","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1200\/JCO.1995.13.8.2109","article-title":"Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay","volume":"13","author":"Hoon","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.4065\/mcp.2011.0287_bib68","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ijc.20347","article-title":"Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma","volume":"111","author":"Mocellin","year":"2004","journal-title":"Int J Cancer"},{"key":"10.4065\/mcp.2011.0287_bib69","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2002.08.009","article-title":"Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon","volume":"20","author":"Mellado","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.4065\/mcp.2011.0287_bib70","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2003.01.128","article-title":"Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction","volume":"21","author":"Palmieri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.4065\/mcp.2011.0287_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/CCLM.2009.009","article-title":"Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance","volume":"47","author":"Nezos","year":"2009","journal-title":"Clin Chem Lab Med"},{"key":"10.4065\/mcp.2011.0287_bib72","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1373\/49.9.1450","article-title":"Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanoma","volume":"49","author":"Szenajch","year":"2003","journal-title":"Clin Chem"},{"key":"10.4065\/mcp.2011.0287_bib73","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1515\/CCLM.2006.260","article-title":"Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics","volume":"44","author":"Mitropapas","year":"2006","journal-title":"Clin Chem Lab Med"},{"key":"10.4065\/mcp.2011.0287_bib74","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.bjc.6690436","article-title":"Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR","volume":"80","author":"de Vries","year":"1999","journal-title":"Br J Cancer"},{"key":"10.4065\/mcp.2011.0287_bib75","first-page":"2253","article-title":"Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence","volume":"60","author":"Hoon","year":"2000","journal-title":"Cancer Res"},{"key":"10.4065\/mcp.2011.0287_bib76","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1373\/clinchem.2006.081828","article-title":"Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers","volume":"53","author":"Xi","year":"2007","journal-title":"Clin Chem"},{"key":"10.4065\/mcp.2011.0287_bib77","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.2005.04.098","article-title":"Molecular staging in stage II and III melanoma patients and its effect on long-term survival","volume":"23","author":"Voit","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4065\/mcp.2011.0287_bib78","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1200\/JCO.1998.16.5.1760","article-title":"Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma","volume":"16","author":"Curry","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.4065\/mcp.2011.0287_bib79","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/sj.bjc.6601197","article-title":"Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients","volume":"89","author":"Osella-Abate","year":"2003","journal-title":"Br J Cancer"},{"key":"10.4065\/mcp.2011.0287_bib80","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/CMR.0b013e3280a60878","article-title":"Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma","volume":"17","author":"Visus","year":"2007","journal-title":"Melanoma Res"},{"key":"10.4065\/mcp.2011.0287_bib81","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/00008390-200404000-00018","article-title":"Clinical significance of sequential tyrosinase expression in the peripheral blood of disease-free melanoma patients: a review of literature data","volume":"14","author":"Quaglino","year":"2004","journal-title":"Melanoma Res"},{"key":"10.4065\/mcp.2011.0287_bib82","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/sj.eye.6702322","article-title":"Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma: a prospective longitudinal study","volume":"21","author":"Callejo","year":"2007","journal-title":"Eye (Lond)"},{"key":"10.4065\/mcp.2011.0287_bib83","first-page":"325","article-title":"A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma","volume":"137","author":"Tsao","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.4065\/mcp.2011.0287_bib84","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1440-169X.2005.00835.x","article-title":"Pax3 transcripts in melanoblast development","volume":"47","author":"Blake","year":"2005","journal-title":"Dev Growth Differ"},{"key":"10.4065\/mcp.2011.0287_bib85","first-page":"1075","article-title":"Expression of genes for microphthalmia isoforms, Pax3 and MSG1, in human melanomas","volume":"45","author":"Vachtenheim","year":"1999","journal-title":"Cell Mol Biol (Noisy-legrand)"},{"key":"10.4065\/mcp.2011.0287_bib86","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00008390-200008000-00007","article-title":"Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells","volume":"10","author":"Schrader","year":"2000","journal-title":"Melanoma Res"},{"key":"10.4065\/mcp.2011.0287_bib87","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/modpathol.3801008","article-title":"RT in situ PCR detection of MART-1 and TRP-2 mRNA in formalin-fixed, paraffin-embedded tissues of melanoma and nevi","volume":"21","author":"Itakura","year":"2008","journal-title":"Mod Pathol"},{"key":"10.4065\/mcp.2011.0287_bib88","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1468-3083.2007.02329.x","article-title":"Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method","volume":"22","author":"Arenberger","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.4065\/mcp.2011.0287_bib89","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00002371-200501000-00002","article-title":"Systematic identification of human melanoma antigens using serial analysis of gene expression (SAGE)","volume":"28","author":"Matsuzaki","year":"2005","journal-title":"J Immunother"},{"key":"10.4065\/mcp.2011.0287_bib90","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0749.2005.00269.x","article-title":"The Silver locus product Pmel17\/gp100\/Silv\/ME20: controversial in name and in function","volume":"18","author":"Theos","year":"2005","journal-title":"Pigment Cell Res"},{"key":"10.4065\/mcp.2011.0287_bib91","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0002-9440(10)63657-7","article-title":"MLANA\/MART1 and SILV\/PMEL17\/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma","volume":"163","author":"Du","year":"2003","journal-title":"Am J Pathol"},{"key":"10.4065\/mcp.2011.0287_bib92","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0923-1811(99)00098-5","article-title":"gp100 mRNA is more sensitive than tyrosinase mRNA for RT-PCR amplification to detect circulating melanoma cells in peripheral blood of melanoma patients","volume":"23","author":"Tsukamoto","year":"2000","journal-title":"J Dermatol Sci"},{"key":"10.4065\/mcp.2011.0287_bib93","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1078-0432.CCR-0610-3","article-title":"Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction","volume":"10","author":"Keilholz","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.4065\/mcp.2011.0287_bib94","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nature03269","article-title":"Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression","volume":"433","author":"Carreira","year":"2005","journal-title":"Nature"},{"key":"10.4065\/mcp.2011.0287_bib95","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature03664","article-title":"Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma","volume":"436","author":"Garraway","year":"2005","journal-title":"Nature"},{"key":"10.4065\/mcp.2011.0287_bib96","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/1078-0432.CCR-05-1847","article-title":"Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients","volume":"12","author":"Koyanagi","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.4065\/mcp.2011.0287_bib97","first-page":"142","article-title":"Microphthalmia-associated transcription factor and tyrosinase as markers of melanoma cells in blood of patients with melanoma","volume":"45","author":"Samija","year":"2004","journal-title":"Croat Med J"},{"key":"10.4065\/mcp.2011.0287_bib98","doi-asserted-by":"crossref","first-page":"6344","DOI":"10.1158\/1078-0432.CCR-06-2682","article-title":"Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response","volume":"13","author":"Ugurel","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.4065\/mcp.2011.0287_bib99","first-page":"1371","article-title":"Melanoma-associated antigens as messenger RNA detection markers for melanoma","volume":"57","author":"Sarantou","year":"1997","journal-title":"Cancer Res"},{"key":"10.4065\/mcp.2011.0287_bib100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00008390-200410000-00005","article-title":"Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III\/IV melanoma patients","volume":"14","author":"Enk","year":"2004","journal-title":"Melanoma Res"},{"key":"10.4065\/mcp.2011.0287_bib101","first-page":"1497","article-title":"Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma","volume":"9","author":"Reynolds","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.4065\/mcp.2011.0287_bib102","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1200\/JCO.2005.02.0958","article-title":"Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial","volume":"23","author":"Koyanagi","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4065\/mcp.2011.0287_bib103","first-page":"1843","article-title":"Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients","volume":"5","author":"Mellado","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.4065\/mcp.2011.0287_bib104","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1083\/jcb.110.4.1227","article-title":"EndoCAM: a novel endothelial cell-cell adhesion molecule","volume":"110","author":"Albelda","year":"1990","journal-title":"J Cell Biol"},{"key":"10.4065\/mcp.2011.0287_bib105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00008390-200102000-00008","article-title":"Detection of circulating melanoma cells in peripheral blood by a two-marker RT-PCR assay","volume":"11","author":"Kulik","year":"2001","journal-title":"Melanoma Res"},{"key":"10.4065\/mcp.2011.0287_bib106","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1373\/clinchem.2004.045096","article-title":"Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients","volume":"51","author":"Koyanagi","year":"2005","journal-title":"Clin Chem"},{"key":"10.4065\/mcp.2011.0287_bib107","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1535-7163.MCT-04-0297","article-title":"Raf kinase as a target for anticancer therapeutics","volume":"4","author":"Sridhar","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.4065\/mcp.2011.0287_bib108","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.2146\/ajhp080461","article-title":"Targeting metastatic melanoma","volume":"65","author":"Poust","year":"2008","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.4065\/mcp.2011.0287_bib109","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.hoc.2009.04.001","article-title":"BRAF signaling and targeted therapies in melanoma","volume":"23","author":"Dhomen","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.4065\/mcp.2011.0287_bib110","first-page":"3883","article-title":"BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma","volume":"63","author":"Dong","year":"2003","journal-title":"Cancer Res"},{"key":"10.4065\/mcp.2011.0287_bib111","first-page":"6483","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.4065\/mcp.2011.0287_bib112","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1477-3163-3-6","article-title":"Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis","volume":"3","author":"Houben","year":"2004","journal-title":"J Carcinog"},{"key":"10.4065\/mcp.2011.0287_bib113","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1078-0432.CCR-06-2120","article-title":"Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy","volume":"13","author":"Shinozaki","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.4065\/mcp.2011.0287_bib114","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1349-7006.2010.01650.x","article-title":"Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis","volume":"101","author":"Kosaka","year":"2010","journal-title":"Cancer Sci"},{"key":"10.4065\/mcp.2011.0287_bib115","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2141.2008.07077.x","article-title":"Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma","volume":"141","author":"Lawrie","year":"2008","journal-title":"Br J Haematol"},{"key":"10.4065\/mcp.2011.0287_bib116","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4065\/mcp.2011.0287_bib117","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygyno.2008.04.033","article-title":"MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer","volume":"110","author":"Taylor","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.4065\/mcp.2011.0287_bib118","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1756-0500-2-89","article-title":"Circulating microRNAs in breast cancer and healthy subjects","volume":"2","author":"Zhu","year":"2009","journal-title":"BMC Res Notes"},{"issue":"7","key":"10.4065\/mcp.2011.0287_bib119","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/sj.bjc.6605608","article-title":"Circulating microRNAs in plasma of patients with gastric cancers","volume":"102","author":"Tsujiura","year":"2010","journal-title":"Br J Cancer"},{"issue":"9","key":"10.4065\/mcp.2011.0287_bib120","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1158\/1940-6207.CAPR-09-0094","article-title":"MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease","volume":"2","author":"Wang","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.4065\/mcp.2011.0287_bib121","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gut.2008.167817","article-title":"Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening","volume":"58","author":"Ng","year":"2009","journal-title":"Gut"},{"key":"10.4065\/mcp.2011.0287_bib122","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1200\/JCO.2005.03.164","article-title":"Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients","volume":"23","author":"Mian","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611652397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611652397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T03:43:20Z","timestamp":1712979800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611652397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":122,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0025619611652397"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2011.0287","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating Serologic and Molecular Biomarkers in Malignant Melanoma","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2011.0287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}